Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Inclusion Criteria: 1. Written informed consent had to be obtained before any assessment was performed; 2. Patients had to be cooperative, willing to participate in the study assessments, and be able to report AEs (adverse events) themselves or have a caregiver who can record and report the events; 3. Total exposure to BGG492 treatment in Study BGG492A2207 and/or BGG492A2212 had to have been greater than 28 days 4. At least 1 year had to have elapsed since the patient received his or her last dose of BGG492. Exclusion Criteria: \- There were no exclusion criteria for this study. All patients meeting the inclusion criteria were eligible to participate in the follow-up safety assessments